IBRI Strategic Framework

The IBRI is an important part of the next generation of the Indiana life sciences ecosystem. We act as a connector, covener and collaborator, to catalyze and complement the burgeoning academic and industrial life sciences research community in Indiana. This allows us to solve the most challenging health problems not only for Hoosiers, but for people all over the world.

A Unique Model

Our unique model – an independent, not-for-profit organization with a laser-focused mission – is connecting the best minds from industry, academia and the public sector to collaboratively tackle diabetes, cardio-metabolic diseases and nutrition, while remaining sufficiently agile to allow the science to evolve in areas where next-generation health problems are evident, and where solutions must be found.

The IBRI is essential. Despite Indiana’s robust life sciences ecosystem, the state is not yet a life sciences destination for a new generation of entrepreneurs and innovators. The IBRI was created to:

  • Elevate Indiana’s reputation, thus attracting and retaining top talent.
  • Link Indiana’s excellence in life sciences to the health needs of Hoosiers.
  • Create a highly marketable culture of collaboration and commercialization between industry and academia.
  • Eliminate the silos that exist within and between industry, academia and the public sector to expedite innovative solutions

IBRI Goals

The IBRI was created as an honest broker to eliminate barriers and foster team science. We bring partners together to accelerate research and find solutions faster than ever before for the people of Indiana and beyond. Our motto, Discovery With Purpose, reflects our commitment to translate scientific discovery into improved outcomes for patients.

  • Catalyze opportunities through the industry-inspired design of solutions for health problems associated with diabetes, cardiovascular disease and nutrition.
  • Complement and enhance the Indiana life sciences ecosystem by linking life science expertise to Hoosier health.
  • Connect industry, academia and the public sector to expedite solutions for the most pressing health issues related to cardio-metabolic diseases, including diabetes and poor nutrition.

Industry-inspired and purpose-driven opportunities

  • Applied research activities defined or specifically requested by the life sciences industries in the Indiana ecosystem.
  • Research that is sponsored by industry partners.
  • Problems in need of solutions identified by industry partners (not necessarily sponsored or paid for by industry).
  • Outcomes and technologies meeting the standards of industry partners or a product an industry partner would license or commercialize.

The founders of the IBRI in 2013 were Lilly Endowment, the State of Indiana, Eli Lilly and Company Foundation, Roche Diagnostics, Dow AgroSciences (now Corteva Agriscience), Eli Lilly and Company, Indiana University Health, Cook Medical, Indiana University School of Medicine and the City of Indianapolis

Four focused research centers

Applied Data Sciences Center

The Applied Data Sciences Center (ADSC) aims to become a nationally recognized collaboration hub located in Indianapolis, driving multi-organizational and trans-disciplinary projects that leverage integrated yet disparate data sources and advanced data analytics to provide insight into cardio-metabolic disease, including community health, nutrition and related challenges.

IBRI Diabetes Center

The IBRI Diabetes Center (IDC) is highly collaborative and structured to support basic science research seeking to understand the disease while achieving technological breakthroughs in the way we diagnose, treat and manage diabetes in Indiana and beyond.

The research core of the IDC is the Lilly Diabetes Center of Excellence (LDCE), a collaboration between Eli Lilly and Company, the Indiana University School of Medicine and the IBRI. The LDCE aims to become a nexus of strategically aligned basic diabetes research in Indianapolis. The IDC also includes the IBRI's Regenerative Medicine and Metabolic Biology group, which studies beta cell regeneration.

Pharmaceutical Biotechnology Center

The Pharmaceutical Biotechnology Center (PBC) addresses human and animal health by developing biotherapeutics (monoclonal antibodies, peptides and proteins) and vaccines targeting cardiometabolic diseases, diabetes and nutritional health.

The PBC covers the entire value chain from target characterization and lead identification through to candidate evaluation and early-phase clinical development.

Single Cell Analytics Center

The Single Cell Analytics Center (SCAC) is innovating the next generation of diagnostic systems and methods to enable the development of new standards in patient care. The SCAC aspires to be recognized as a center of excellence for the rapid commercial development of bioanalytical technologies as measured by the ability to raise external investment and convert bioanalytical platforms into

The IDC also includes the Regenerative Medicine and Metabolic Biology group, which explores beta cell regeneration.

Every gift makes an impact.

Our research is made possible by your generous gift and it will help lead to solutions to major health challenges affecting almost one out of every three people globally.

donate now